Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from INVO Fertility ( (IVF) ).
On April 23, 2026, INVO Fertility, Inc. received a Nasdaq notice that it was not in compliance with listing rules after failing to timely file its Form 10‑K for the year ended Dec. 31, 2025, a delay the company attributed to the need for additional review of complex tax, warrant, and variable interest entity accounting. The notification does not immediately affect the listing or trading of INVO’s common stock under the ticker IVF, and the company has 60 days to submit a compliance plan and potentially up to 180 days from the report’s due date to regain compliance, with an appeals process available if its plan is rejected.
On April 29, 2026, INVO publicly disclosed the Nasdaq deficiency notice, emphasizing that it is working diligently to complete and file the overdue annual report as promptly as possible, a step that will be closely watched by investors given the implications of sustained non‑compliance for its Nasdaq listing and overall market standing.
The most recent analyst rating on (IVF) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.
Spark’s Take on IVF Stock
According to Spark, TipRanks’ AI Analyst, IVF is a Neutral.
The score is primarily held back by weak financial performance (persistent losses, declining gross margin, and negative operating/free cash flow). Technicals are only mildly supportive, while valuation lacks support due to negative earnings and no dividend data. Corporate events are mixed—growth initiatives and financing help, but dilution risk and the reverse split temper the upside.
To see Spark’s full report on IVF stock, click here.
More about INVO Fertility
INVO Fertility, Inc. is a healthcare services fertility company focused on expanding access to assisted reproductive technology by building, acquiring, and operating fertility clinics in the U.S. Its strategy centers on “INVO Centers” that offer the intravaginal culture procedure enabled by the proprietary INVOcell medical device, alongside profitable IVF clinics and third‑party distribution of INVOcell.
The company currently operates four fertility clinics in the United States and positions the INVOcell‑enabled intravaginal culture procedure as a more intimate and affordable alternative to traditional IVF, which it believes can deliver comparable results at a fraction of the cost and superior effectiveness to intrauterine insemination, targeting patients seeking lower‑cost advanced reproductive care.
Average Trading Volume: 97,211
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.3M
Find detailed analytics on IVF stock on TipRanks’ Stock Analysis page.